key: cord-1048468-scdktwnf
authors: Beun, Robert; Kusadasi, Nuray; Sikma, Maaike; Westerink, Jan; Huisman, Albert
title: Thromboembolic events and apparent heparin resistance in patients infected with SARS‐CoV‐2
date: 2020-04-20
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13230
sha: 5afea8fed7c157670796cac56ff6ea34431b19c2
doc_id: 1048468
cord_uid: scdktwnf

In March 2020, the global healthcare system is overwhelmed by patients infected with SARS‐CoV‐2, which is the cause of the coronavirus pandemic (Covid‐2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived.

In March 2020, the global healthcare system is overwhelmed by patients infected with SARS-CoV-2, which is the cause of the coronavirus pandemic (Covid-2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived 1 . Although no data has been presented or published, clinical experience suggests that this coagulopathy is associated with an increased risk for both venous and arterial thrombosis. Treatment of thrombosis in the setting of profound coagulopathy may be hampered by the inability to use the aPTT ratio when treating with unfractionated heparin (UHF). We provide data from our center and provide guidance for treatment of perceived heparin resistance associated with the coagulopathy in patients with SARS-CoV-2 infection. Table 2 provides data on four patients with an indication for therapeutic anticoagulation and profound coagulopathy at admission or diagnosis of a thromboembolic event.

Treatment in all four patients was complicated by necessitating very high UFH doses to achieve perceived adequate coagulation, based on the aPTT ratio.

>Table2 This rare phenomenon defined as the need for high dose UFH of more than 35,000 IU/day to achieve the target aPTT ratio or the impossibility of doing so is called heparin resistance. In an attempt to elucidate the possible causal factor(s) of heparin resistance in patients with a SARS-CoV-2 infection, we measured the levels of the coagulation associated factors such as factor VIII, d-dimer, fibrinogen and antithrombin in these patients. Coagulation assays were measured in the central ISO-15189 accredited laboratory using an ACL Top 750 LAS coagulation analyzer (Werfen diagnostics, Barcelona, Spain) using Coamatic factor VIII reagent (chromogenic factor VIII), QFA Thrombin reagent (fibrinogen), liquid antithrombin reagent (antithrombin) and d-dimer HS500 reagent (d-dimer) all obtained from Werfen diagnostics (Barcelona, Spain). Platelets were measured using an Alinity Hq hematology analyzer (Abbott Diagnostics, Santa Clara, CA, USA). A formal ethics review for this study was deemed unnecessary by the local Ethics Committee.

Factor VIII was found to be extremely increased in SARS-CoV-2 patients, also fibrinogen and d-dimer were elevated, while almost all of the antithrombin levels were in the normal range.

High factor VIII level is a common cause of apparent heparin resistance 2,3 . Increased factor VIII levels 

Based on the limited SARS-CoV-2 data and our own experience, we suggest to monitor the heparin activity of UFH treatment based on anti-Xa levels with a target value of 0.3 -0.7 U/L in all patients with SARS-CoV-2 instead of treatment based on aPTT levels 5,6,7 . Accepted Article

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient

Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels

Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin

Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study

Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin

Zumberg MS Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion

Blood samples were drawn on the day of admission to the ICU, or on the first day of signs of thromboembolic events. Conversion factor for factor VIII and